Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have received an average rating of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $35.25.

ANRO has been the subject of several research analyst reports. JonesTrading reduced their price objective on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 target price on shares of Alto Neuroscience in a report on Monday, March 16th. BTIG Research lifted their target price on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Weiss Ratings raised Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Alto Neuroscience in a report on Wednesday, May 27th.

Alto Neuroscience Trading Up 0.6%

Alto Neuroscience stock opened at $21.57 on Friday. The stock has a 50-day moving average of $22.71 and a two-hundred day moving average of $19.51. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. Alto Neuroscience has a one year low of $2.15 and a one year high of $28.44. The stock has a market cap of $756.72 million, a PE ratio of -8.91 and a beta of 1.22.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). On average, research analysts anticipate that Alto Neuroscience will post -3.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently modified their holdings of ANRO. Invesco Ltd. acquired a new stake in shares of Alto Neuroscience during the first quarter worth about $67,000. AQR Capital Management LLC acquired a new stake in shares of Alto Neuroscience during the first quarter worth about $52,000. Marshall Wace LLP lifted its holdings in shares of Alto Neuroscience by 9.9% during the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after purchasing an additional 84,417 shares during the period. Jane Street Group LLC acquired a new stake in shares of Alto Neuroscience during the second quarter worth about $240,000. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Alto Neuroscience by 85.9% during the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.